May 4, 2019: Dale Yuzuki posted an article on LinkedIn
⚗️Dale YuzukiInterested in how digital PCR is used to analyze circulating tumor DNA (ctDNA) as a liquid biopsy for early response prediction and monitoring disease progression? Webinar May 8 11am ET
⚗️Dale YuzukiInterested in how digital PCR is used to analyze circulating tumor DNA (ctDNA) as a liquid biopsy for early response prediction and monitoring disease progression? GenomeWebinar May 8 11am ET / 8am PT
Quantification of DNA sequence tags from engineered constructs such as plasmids, transposons, or other transgenes underlies many functional genomics measurements. Typically, such measurements rely on PCR followed by next-generation sequencing....
New Chinese investment is helping Cambridge genomics services innovator Congenica to scale in China and the Unites States. The UK company has raised an additional £13.25 million to hoist its completed Series B round to £23.3m. Parkwalk Advisors led...
⚗️Dale YuzukiChina cash helps Congenica raise extra £13.25m to take Series B to £23.3m | Business Weekly
<p>Identifying the mutational landscape of tumours from cell-free DNA in the blood could help diagnostics in cancer. Here, the authors present ichorCNA, software that quantifies tumour content in cell free DNA, and they demonstrate that cell-free...
⚗️Dale YuzukiScalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors | Nature Comm